Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Citron Rho Interacting Kinase (CRIK) Regulates Survival in IL-6 Dependent Multiple Myeloma Cells.

Hai T. Ngo, Alexey A. Leontovich, PhD, Aldo M. Roccaro, MD, PhD, Abdel Kareem Azab, Bpharm, PhD, Judith M. Runnels, PhD, Feda Azab, BPharm, Antonio Sacco, Phong Quang, Kenneth C. Anderson, MD, Irene M. Ghobrial, M.D.

Blood (2009) 114 (22): 1825.

https://doi.org/10.1182/blood.V114.22.1825.1825

Published: 2009

Journal Articles

The Effect of the CXCR4 Inhibitors, AMD3100 and AMD3465, in Multiple Myeloma Cell Homing and Its Interaction with the Bone Marrow Microenvironment.

Judith M. Runnels, PhD, Abdel Kareem Azab, Bpharm, PhD, Costas Pitsillides, PhD, Jonathan Farag, Juwell Wu, Aldo M. Roccaro, MD, PhD, Patricia Maiso, PhD, Charles P. Lin, PhD, Irene M. Ghobrial, M.D.

Blood (2009) 114 (22): 1826.

https://doi.org/10.1182/blood.V114.22.1826.1826

Published: 2009

Journal Articles

Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in Waldenstrom's Macroglubulinemia and Plays a Major Role in Its Interaction with the Bone Marrow Microenvironment.

Abdel Kareem Azab, Bpharm, PhD, Feda Azab, BPharm, Aldo M. Roccaro, MD, PhD, Antonio Sacco, Phong Quang, Hai T. Ngo, Molly R Melhem, Judith M. Runnels, PhD, Patricia Maiso, PhD, Irene M. Ghobrial, M.D.

Blood (2009) 114 (22): 2935.

https://doi.org/10.1182/blood.V114.22.2935.2935

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Fangxin Hong, PhD, Swaminathan Padmanabhan, MD, Ashraf Z. Badros, MD, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Edie Weller, PhD, Jeffrey Matous

Blood (2009) 114 (22): 2727.

https://doi.org/10.1182/blood.V114.22.2727.2727

Published: 2009

Journal Articles

An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.

Noopur Raje, MD., Paul Richardson, M.D., Parameswaran N Hari, MD, Anuj Mahindra, Sarah Kaster, BS, Christine Connolly, Linda Rivera, Gaurav Chetri, Sarah Dean, Paulette Jacobs, Ayman Saad, MD, Jacob Laubach, Irene M. Ghobrial, M.D., Robert L Schlossman, M.D., Ph.D., Jennifer Adams, Wendy Makrides, Edie Weller, PhD, Nikhil Munshi, M.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3856.

https://doi.org/10.1182/blood.V114.22.3856.3856

Published: 2009

Journal Articles

RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia.

Steven Vesole, Xiaoying Jia, Aldo M. Roccaro, MD, PhD, Antonio Sacco, Hai T. Ngo, Feda Azab, BPharm, Abdel Kareem Azab, BPharm, PhD, Molly R Melhem, Judith M. Runnels, PhD, Phong Quang, Kenneth C. Anderson, MD, Irene M. Ghobrial, M.D.

Blood (2009) 114 (22): 3732.

https://doi.org/10.1182/blood.V114.22.3732.3732

Published: 2009

Journal Articles

The Role of FGFR in the Progression of Waldenstrom's Macroglubulinemia and the Effect of Its Inhibition by TKI-258.

Feda Azab, BPharm, Abdel Kareem Azab, Bpharm, PhD, Aldo M. Roccaro, MD, PhD, Antonio Sacco, Phong Quang, Hai T Ngo, Molly R Melhem, Judith M. Runnels, PhD, Patricia Maiso, PhD, Irene M Ghobrial, M.D.

Blood (2009) 114 (22): 3737.

https://doi.org/10.1182/blood.V114.22.3737.3737

Published: 2009

Journal Articles

Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM).

Xavier Leleu, Renee Leduc, Meghan Rourke, Stacey Chuma, Amy Sam, Brianna Harris, Janet Kunsman, NP, Irene M. Ghobrial, M.D.

Blood (2009) 114 (22): 3952.

https://doi.org/10.1182/blood.V114.22.3952.3952

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Swaminathan Padmanabhan, Ashraf Z. Badros, MD, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Jeffrey Matous

Blood (2009) 114 (22): 3752.

https://doi.org/10.1182/blood.V114.22.3752.3752

Published: 2009

Journal Articles

Role of Hypoxia in the Progression and Dissemination of Multiple Myeloma.

Abdel Kareem Azab, Bpharm, PhD, Phong Quang, Feda Azab, BPharm, Aldo M. Roccaro, MD, PhD, Antonio Sacco, Judith M. Runnels, PhD, Hai T. Ngo, Molly R Melhem, Patricia Maiso, PhD, Kenneth C. Anderson, MD, Charles P. Lin, PhD, Irene M. Ghobrial, M.D.

Blood (2009) 114 (22): 421.

https://doi.org/10.1182/blood.V114.22.421.421

Published: 2009

Journal Articles

Role of Selectins in the Pathogenesis of Multiple Myeloma.

Abdel Kareem Azab, Bpharm, PhD, Phong Quang, Feda Azab, BPharm, Costas M Pitsillides, John T Patton, Theodore Smith, Arun Sarkar, Judith M. Runnels, PhD, Aldo M. Roccaro, MD, PhD, Antonio Sacco, Hai T. Ngo, Molly R Melhem, Patricia Maiso, PhD, Kenneth C. Anderson, MD, Charles P. Lin, PhD, John L. Magnani, Irene M. Ghobrial, M.D.

Blood (2009) 114 (22): 951.

https://doi.org/10.1182/blood.V114.22.951.951

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

Irene M. Ghobrial, M.D., Ravi Vij, MD, Nikhil C. Munshi, Robert L Schlossman, M.D., Ph.D., Jacob Laubach, Erica L. Campagnaro, MD, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, NP, Akari M. Dollard, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D.

Blood (2009) 114 (22): 748.

https://doi.org/10.1182/blood.V114.22.748.748

Published: 2009

Journal Articles

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Blood (2009) 114 (22): 587.

https://doi.org/10.1182/blood.V114.22.587.587

Published: 2009

Journal Articles

PET/CT a New Marker of Response in Waldenstrom Macroglobulinemia (WM).

Xavier Leleu, Renee Leduc, Meghan Rourke, Brianna Harris, Aldo M. Roccaro, MD, PhD, Dilek Yarar, Jonathan Farag, Irene M. Ghobrial, M.D.

Blood (2009) 114 (22): 1937.

https://doi.org/10.1182/blood.V114.22.1937.1937

Published: 2009

Journal Articles

In Vivo Imaging Model of Multiple Myeloma and Its Cellular Interaction with the Bone Marrow Microenvironment

Judith Runnels, PhD, Alicia Carlson, PhD, Costas Pitsillides, PhD, Joel Spencer, PhD, Juwell Wu, Abdel kareem Azab, PhD, Aldo M. Roccaro, MD, PhD, Anne-Sophie Moreau, MD, Xavier Leleu, MD, PhD, Andrew Kung, MD, PhD, Scott J. Rodig, MD, PhD, Kenneth C Anderson, MD, Charles P. Lin, PhD, Irene M. Ghobrial, M.D.

Blood (2008) 112 (11): 647.

https://doi.org/10.1182/blood.V112.11.647.647

Published: 2008

Journal Articles

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

Blood (2008) 112 (11): 870.

https://doi.org/10.1182/blood.V112.11.870.870

Published: 2008

Journal Articles

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, M.D., Jeffrey Matous, MD, Swaminathan Padmanabhan, MD, Ashraf Badros, MD, Robert Schlossman, MD, Stacey Chuma, RN, Renee Leduc1, Marybeth Nelson, PA, Kelly O’Connor, Amy Sam, Brianna Harris, Jacob Soumerai, Diane Warren, Ann Birner, Nikhil Munshi, MD, Steven P. Treon, MD, PhD, Kenneth C. Anderson, MD, Paul Richardson, MD

Blood (2008) 112 (11): 832.

https://doi.org/10.1182/blood.V112.11.832.832

Published: 2008

Journal Articles

Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).

Irene M. Ghobrial, M.D., Xavier Leleu, MD, PhD, Nancy Rubin, MD, Wanling Xie, Fangxin Hong, Stacey Chuma, RN, Renee Leduc, Marybeth Nelson, PA, Kelly O’Connor, Amy Sam, Brianna Harris, Diane Warren, Peter Sportelli, Steven P. Treon, MD, PhD, Edie Weller, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2008) 112 (11): 1010.

https://doi.org/10.1182/blood.V112.11.1010.1010

Published: 2008

Journal Articles

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

Irene M. Ghobrial, M.D., Stacey Chuma, RN, Amy Sam, Renee Leduc, Marybeth Nelson, PA, Kelly O’Connor, Brianna Harris, Jacob Soumerai, Diane Warren, Eric Jacobsen, MD, Daniel DeAngelo, MD, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Thomas E. Witzig, MD, Steven P. Treon, MD, PhD

Blood (2008) 112 (11): 1011.

https://doi.org/10.1182/blood.V112.11.1011.1011

Published: 2008

Journal Articles

CXCR7 Regulates SDF-1 Induced Adhesion and Homing in Multiple Myeloma.

Nicholas Burwick, MD, Anne-Sophie Moreau, MD, Xiaoying Jia, Xavier Leleu, MD, PhD, Judith Runnels, Hai T. Ngo, Molly R. Melhem, Aldo M. Roccaro, MD, PhD, Abdel kareem Azab, PhD, Irene M. Ghobrial, M.D.

Blood (2008) 112 (11): 1674.

https://doi.org/10.1182/blood.V112.11.1674.1674

Published: 2008

NARROW

Citron Rho Interacting Kinase (CRIK) Regulates Survival in IL-6 Dependent Multiple Myeloma Cells.

The Effect of the CXCR4 Inhibitors, AMD3100 and AMD3465, in Multiple Myeloma Cell Homing and Its Interaction with the Bone Marrow Microenvironment.

Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in Waldenstrom's Macroglubulinemia and Plays a Major Role in Its Interaction with the Bone Marrow Microenvironment.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.

RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia.

The Role of FGFR in the Progression of Waldenstrom's Macroglubulinemia and the Effect of Its Inhibition by TKI-258.

Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM).

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

Role of Hypoxia in the Progression and Dissemination of Multiple Myeloma.

Role of Selectins in the Pathogenesis of Multiple Myeloma.

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

PET/CT a New Marker of Response in Waldenstrom Macroglobulinemia (WM).

In Vivo Imaging Model of Multiple Myeloma and Its Cellular Interaction with the Bone Marrow Microenvironment

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

CXCR7 Regulates SDF-1 Induced Adhesion and Homing in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only